Evidence-led peptide reference
BPC-157 + TB-500 research guide
Also known as: Wolverine blend
Updated 10 October 2026 · Editorial standards
Two distinct experimental materials commonly grouped together in preclinical repair research.
Identity and context
What is BPC-157 + TB-500?
BPC-157 is a synthetic 15-amino-acid peptide described in the literature as a fragment related to a gastric protein. TB-500 is a commercial research name commonly associated with thymosin-beta-4-related material. They are not the same molecule and their evidence bases should not be merged.
The informal name “Wolverine” describes a marketed combination rather than a recognised, approved clinical formulation. For TB-500 in particular, the precise amino-acid sequence and whether the material is full thymosin beta-4 or a fragment should be confirmed rather than inferred from the label.
Mechanism under investigation
How is BPC-157 + TB-500 studied?
BPC-157 studies have examined nitric-oxide signalling, angiogenesis, inflammatory pathways and cell migration in preclinical injury models. Thymosin beta-4 research includes actin binding, cell migration, angiogenesis and tissue-remodelling biology. Similar research themes do not make the substances interchangeable.
A combination can introduce different stability, identity and interaction questions. Evidence for either individual compound does not prove that a blended formulation is effective or safe.
Research map
Main areas of interest
Tendon, muscle and ligament models
Animal and laboratory models explore cell migration, repair signalling and tissue organisation after experimental injury.
Gastrointestinal models
BPC-157 has a substantial preclinical literature in gastric and intestinal injury, but controlled human confirmation is lacking.
Wound and vascular biology
Thymosin beta-4-related research examines actin, angiogenesis and wound responses across experimental systems.
Strength of evidence
What does the evidence actually show?
Evidence is separated by level because a cell experiment, an animal model, a human trial and a regulatory decision answer different questions.
Critical reading
Limitations and unanswered questions
- Animal injury models cannot establish human recovery speed or safety.
- The exact identity of material sold as TB-500 can be ambiguous without sequence-specific analysis.
- A blend COA should distinguish and quantify both components rather than report one combined purity figure.
- Anti-doping rules and sport-governing-body restrictions may apply independently of marketing claims.
Analytical context
What a certificate of analysis can—and cannot—tell you
A certificate of analysis is a report about the particular submitted sample and tests named on that report. It can help document identity, measured amount or purity when suitable methods were used. It does not prove that every batch is identical, that a material is sterile or endotoxin-free, that it is clinically effective, or that it is approved for human use.
Learn how to read a peptide COA →Questions answered
BPC-157 + TB-500 FAQs
Are BPC-157 and TB-500 the same peptide?
No. They have different structures, origins and research histories.
What does Wolverine blend mean?
It is an informal commercial name for a combination, not an approved medicine or standard scientific formulation.
Has BPC-157 been proven in people?
No robust body of replicated controlled human trials currently establishes the broad recovery claims commonly made online.
What should a blend COA identify?
Ideally it should identify and quantify each component separately and state the analytical methods and sample details.
Primary and authoritative reading
Sources and further reading
Sources are provided so readers can inspect the underlying literature and current official information. Inclusion does not mean every claim in a paper has been independently confirmed.
- BPC-157 systematic review ↗Peer-reviewed overview of evidence and translational limitations.
- PubMed thymosin beta-4 literature ↗Indexed research on thymosin beta-4 biology; not proof of a particular TB-500 product.
Source and wording review: 7 October 2026. Prepared with AI assistance; no independent clinical review is claimed. Read the editorial policy or suggest a correction.